Patents by Inventor Subba Reddy Palli

Subba Reddy Palli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Development of polylysine:epigallocatechin-3-o-gallate and dsRNA polyplexes for control of mosquitoes
    Patent number: 11793829
    Abstract: The present invention relates to a polyplex composition for modulating expression of a gene-of-interest in an insect comprising: a crosslinker, a cation, and a molecule for initiating RNA interference (RNAi). The present invention further relates to polyplex compositions for modulating genes of interest in Aedes aegypti. The present invention further relates to methods of modulating a gene-of-interest in an insect, comprising: administering to an insect a polyplex composition for modulating expression of a gene-of-interest in an insect comprising: a crosslinker, a cation, and a molecule for initiating RNA interference (RNAi).
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: October 24, 2023
    Assignee: University of Kentucky Research Foundation
    Inventors: Subba Reddy Palli, Ramesh Dhandapani
  • Modified-RNA nanoparticles for induction of RNA interference
    Patent number: 11571394
    Abstract: Improved RNA interference (RNAi) efficiency in insects is disclosed herein. In particular, certain embodiments of the presently-disclosed subject matter relate to use of nanoformulations of double-stranded RNA (dsRNA) to limit nuclease degradation of the dsRNA, and enhance cellular update and intracellular transport to improve delivery of the dsRNA to enhance RNAi in insects.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: February 7, 2023
    Assignee: University of Kentucky Research Foundation
    Inventors: Subba Reddy Palli, Ramesh Kumar Dhandapani
  • DEVELOPMENT OF POLYLYSINE:EPIGALLOCATECHIN-3-O-GALLATE AND DSRNA POLYPLEXES FOR CONTROL OF MOSQUITOES
    Publication number: 20210060053
    Abstract: The present invention relates to a polyplex composition for modulating expression of a gene-of-interest in an insect comprising: a crosslinker, a cation, and a molecule for initiating RNA interference (RNAi). The present invention further relates to polyplex compositions for modulating genes of interest in Aedes aegypti. The present invention further relates to methods of modulating a gene-of-interest in an insect, comprising: administering to an insect a polyplex composition for modulating expression of a gene-of-interest in an insect comprising: a crosslinker, a cation, and a molecule for initiating RNA interference (RNAi).
    Type: Application
    Filed: August 28, 2020
    Publication date: March 4, 2021
    Inventors: Subba Reddy Palli, Ramesh Dhandapani
  • MODIFIED-RNA NANOPARTICLES FOR INDUCTION OF RNA INTERFERENCE
    Publication number: 20200330395
    Abstract: Improved RNA interference (RNAi) efficiency in insects is disclosed herein. In particular, certain embodiments of the presently-disclosed subject matter relate to use of nanoformulations of double-stranded RNA (dsRNA) to limit nuclease degradation of the dsRNA, and enhance cellular update and intracellular transport to improve delivery of the dsRNA to enhance RNAi in insects.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 22, 2020
    Inventors: Subba Reddy Palli, Ramesh Kumar Dhandapani
  • Novel Substitution Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System
    Publication number: 20190071485
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel nuclear receptors comprising a substitution mutation and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene within a host cell using this inducible gene expression system.
    Type: Application
    Filed: August 30, 2018
    Publication date: March 7, 2019
    Inventors: Subba Reddy Palli, Marianna Zinovievna Kapitskaya
  • Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
    Patent number: 10190124
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: January 29, 2019
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
  • Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
    Patent number: 10087231
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel nuclear receptors comprising a substitution mutation and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene within a host cell using this inducible gene expression system.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 2, 2018
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Marianna Zinovievna Kapitskaya
  • Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System
    Publication number: 20170342440
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: June 9, 2017
    Publication date: November 30, 2017
    Inventors: Subba Reddy PALLI, Mohan Basavaraju KUMAR
  • Novel Ecdysone Receptor/Invertebrate Retinoid X Receptor-Based Inducible Gene Expression System
    Publication number: 20170096672
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: October 4, 2016
    Publication date: April 6, 2017
    Applicant: Intrexon Corporation
    Inventors: Subba Reddy PALLI, Marianna Z. Kapitskaya
  • Chimeric Retinoid X Receptors and Their Use in a Novel Ecdysone Receptor-Based Inducible Gene Expression System
    Publication number: 20170096673
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 6, 2017
    Inventors: Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
  • Novel Substitution Mutant Receptors and Their Use in an Ecdysone Receptor-Based Inducible Gene Expression System
    Publication number: 20170015728
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel nuclear receptors comprising a substitution mutation and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene within a host cell using this inducible gene expression system.
    Type: Application
    Filed: December 17, 2015
    Publication date: January 19, 2017
    Applicant: Intrexon Corporation
    Inventors: Subba Reddy PALLI, Marianna Zinovievna Kapitskaya
  • Ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
    Patent number: 9493540
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: November 15, 2016
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Marianna Zinovievna Kapitskaya
  • Novel Substitution Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System
    Publication number: 20160257964
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: March 14, 2016
    Publication date: September 8, 2016
    Applicant: Intrexon Corporation
    Inventors: Subba Reddy PALLI, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
  • Multiple Inducible Gene Regulation System
    Publication number: 20160122771
    Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 5, 2016
    Inventors: Tarlochan Singh DHADIALLA, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, Mohan Philip
  • Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
    Patent number: 9322026
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 26, 2016
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
  • Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
    Patent number: 9249207
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: February 2, 2016
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Marianna Zinovievna Kapitskaya
  • Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
    Patent number: 9163256
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: October 20, 2015
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Mohan Basavaraju Kumar
  • Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
    Patent number: 9063140
    Abstract: The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: June 23, 2015
    Assignee: Intrexon Corporation
    Inventors: Jianzhong Zhang, Dean Ervin Cress, Subba Reddy Palli, Tarlochan Singh Dhadialla
  • Chimeric Retinoid X Receptors and Their Use in a Novel Ecdysone Receptor-Based Inducible Gene Expression System
    Publication number: 20150150152
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
  • Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
    Patent number: 9029152
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 12, 2015
    Assignee: RheoGene, Inc.
    Inventors: Subba Reddy Palli, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto